Advertisement

ADVERTISEMENT

ASCO

News
ASCO Systemic Therapy Guideline Developed for Advanced HCC
11/25/2020
11/25/2020
Journal of Clinical Pathways
News
First-Line Biosimilar-Based Triplet Effective in HER2-Positive Gastric Cancer
07/08/2020
A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...
A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...
A...
07/08/2020
Journal of Clinical Pathways
News
Oncologist Perception of Efficacy, Safety, and Willingness to Prescribe Biosimilars
06/26/2020
Researchers from CVS Health assessed the expected biosimilar prescribing behaviors of practicing oncologists for originator products bevacizumab, trastuzumab, rituximab, and pegfilgrastim. Biosimilars are a...
Researchers from CVS Health assessed the expected biosimilar prescribing behaviors of practicing oncologists for originator products bevacizumab, trastuzumab, rituximab, and pegfilgrastim. Biosimilars are a...
...
06/26/2020
Journal of Clinical Pathways
News
CancerLinQ Certification Pathway Offers Automated Quality Reporting
06/25/2020
In June 2020, the American Society of Clinical Oncology (ASCO) launched the SmartLinQ Quality Oncology Practice Initiative (QOPI) Certification Pathway for practices participating in the QOPI Certification...
In June 2020, the American Society of Clinical Oncology (ASCO) launched the SmartLinQ Quality Oncology Practice Initiative (QOPI) Certification Pathway for practices participating in the QOPI Certification...
In...
06/25/2020
Journal of Clinical Pathways
Huntsman at Home Program Provides Value Through Patient-Centered Care
Interview
Huntsman at Home Program Provides Value Through Patient-Centered Care
06/23/2020
At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the Huntsman Cancer Institute (HCI) and University of Utah (Salt Lake City, UT) gave the first ever evaluation...
At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the Huntsman Cancer Institute (HCI) and University of Utah (Salt Lake City, UT) gave the first ever evaluation...
At the...
06/23/2020
Journal of Clinical Pathways
News
Evaluating Neutropenia Prevalence After Venetoclax Therapy for CLL
06/23/2020
A study at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) evaluated fixed duration venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)...
A study at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) evaluated fixed duration venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)...
A...
06/23/2020
Journal of Clinical Pathways
News
Cost Savings With Biosimilar in Prophylaxis of Chemo-Induced Febrile Neutropenia
06/19/2020
Researchers from the University of Arizona Cancer Center conducted simulation modeling of cost savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced...
Researchers from the University of Arizona Cancer Center conducted simulation modeling of cost savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced...
...
06/19/2020
Journal of Clinical Pathways
News
Long-Term Follow-Up of BTK Inhibitor in Symptomatic Treatment-Naïve CLL
06/15/2020
Long-term data from ACE-CL-001 further supports the favorable results of acalabrutinib in phase III studies for patients with symptomatic, treatment-naïve chronic lymphocytic leukemia (CLL). Results of the study...
Long-term data from ACE-CL-001 further supports the favorable results of acalabrutinib in phase III studies for patients with symptomatic, treatment-naïve chronic lymphocytic leukemia (CLL). Results of the study...
...
06/15/2020
Journal of Clinical Pathways
News
Cost Savings of Supportive Care Biosimilar in the Medicare OCM Population
06/12/2020
A new study sought to better understand how The Centers for Medicare and Medicaid Services (CMS) reimbursement for pegfilgrastim has been impacted by the introduction of two pegfilgrastim biosimilars into the...
A new study sought to better understand how The Centers for Medicare and Medicaid Services (CMS) reimbursement for pegfilgrastim has been impacted by the introduction of two pegfilgrastim biosimilars into the...
A new...
06/12/2020
Journal of Clinical Pathways
News
Modified MIPI Scoring System Provides Clinical, Biological Prognostic Indicators for MCL
06/11/2020
At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the North American Mantle Cell Lymphoma (MCL) Consortium offered clinical, biological, and genomic markers that...
At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the North American Mantle Cell Lymphoma (MCL) Consortium offered clinical, biological, and genomic markers that...
At the...
06/11/2020
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 6 ⁠–⁠ November 8
NEI Congress
November 7 ⁠–⁠ November 10
ECS
November 8 ⁠–⁠ November 10
WoundCon
November 8
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use